On September 25, the FDA approved imlunestrant, an estrogen receptor antagonist, for adults with estrogen receptor-positive, human epidermal growth factor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy. For more information, read the FDA announcement and the Eli Lilly and Company press release.
On September 25, the FDA approved imlunestrant, an estrogen receptor antagonist, for adults with estrogen receptor-positive, human epidermal growth factor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.
For more information, read the FDA announcement and the Eli Lilly and Company press release.
Posted on 9/26/2025
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
